Corcept Therapeutics Incorporated
DE ˙ DB ˙ US2183521028
63,24 € ↓ -0,74 (-1,16%)
2026-06-05
DEL PRIS
SecurityDE:HTD / Corcept Therapeutics Incorporated
InstitutionKennedy Capital Management, Inc.
Latest Disclosed Ownership304,615 shares
Latest Disclosed Value $ 12,279,031
Kennedy Capital Management, Inc. reports 45.24% increase in ownership of HTD / Corcept Therapeutics Incorporated

On May 13, 2026 - Kennedy Capital Management, Inc. filed a 13F-HR form disclosing ownership of 304,615 shares of Corcept Therapeutics Incorporated (DE:HTD) valued at $10,506,171 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 209,733 shares of Corcept Therapeutics Incorporated. This represents a change in shares of 45.24% during the quarter. The current value of the position is $19,263,853 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F Corcept Therapeutics COM 218352102 304,615 94,882 45.24 12,279 68.25 0.2601
2026-02-13 2025-12-31 13F Corcept Therapeutics COM 218352102 209,733 79,807 61.42 7,299 -32.41 0.1546
2025-11-13 2025-09-30 13F Corcept Therapeutics COM 218352102 129,926 13,913 11.99 10,798 26.81 0.2387
2025-08-13 2025-06-30 13F Corcept Therapeutics COM 218352102 116,013 30,090 35.02 8,515 -13.24 0.2030
2025-05-13 2025-03-31 13F Corcept Therapeutics COM 218352102 85,923 35,272 69.64 9,814 284.56 0.2344
2025-02-13 2024-12-31 13F Corcept Therapeutics COM 218352102 50,651 -249 -0.49 2,552 8.37 0.0567
2024-11-14 2024-09-30 13F Corcept Therapeutics COM 218352102 50,900 50,900 2,356 0.0520
2024-05-15 2024-03-31 13F Corcept Therapeutics Incorporated. COM 218352102 0 -44,929 -100.00 0 -100.00
2024-02-14 2023-12-31 13F Corcept Therapeutics Incorporated. COM 218352102 44,929 44,929 1,459 0.0319
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.